Facing the Trial of Internationalizing Clinical Trials to Developing Countries: Some Evidence from Mexico
AbstractIn pursuit of innovation, developing countries play an increasingly relevant role for multinational pharmaceutical firms. Driven partly by cost considerations but also by some host country-specific scientific and technological factors, global drug companies increasingly relocate part of their drug development activities to those countries. In particular, expansion of clinical trials performed in some of the more advanced developing countries is notable over the last years. This paper critically addresses some of these issues with particular reference to Mexico. The latter case equally illustrates some challenges developing countries face to accommodate and govern local performance of clinical trials according to strict internationally accepted regulatory and ethical principles.
Download InfoIf you experience problems downloading a file, check if you have the proper application to view it first. In case of further problems read the IDEAS help page. Note that these files are not on the IDEAS site. Please be patient as the files may be large.
Bibliographic InfoPaper provided by United Nations University, Maastricht Economic and social Research and training centre on Innovation and Technology in its series UNU-MERIT Working Paper Series with number 023.
Date of creation: 2008
Date of revision:
Contact details of provider:
Web page: http://www.merit.unu.edu
Internationalization of R&D; Governance of clinical trials; Developing countries; Mexico;
Other versions of this item:
- Santiago-Rodriguez, Fernando, 2008. "Facing the Trial of Internationalizing Clinical Trials to Developing Countries: Some Evidence from Mexico," MERIT Working Papers 023, United Nations University - Maastricht Economic and Social Research Institute on Innovation and Technology (MERIT).
- I18 - Health, Education, and Welfare - - Health - - - Government Policy; Regulation; Public Health
- F23 - International Economics - - International Factor Movements and International Business - - - Multinational Firms; International Business
- L65 - Industrial Organization - - Industry Studies: Manufacturing - - - Chemicals; Rubber; Drugs; Biotechnology
- O32 - Economic Development, Technological Change, and Growth - - Technological Change; Research and Development; Intellectual Property Rights - - - Management of Technological Innovation and R&D
This paper has been announced in the following NEP Reports:
- NEP-ALL-2008-04-21 (All new papers)
- NEP-DEV-2008-04-21 (Development)
- NEP-INO-2008-04-21 (Innovation)
Please report citation or reference errors to , or , if you are the registered author of the cited work, log in to your RePEc Author Service profile, click on "citations" and make appropriate adjustments.:
- Kuemmerle, Walter, 1999. "Foreign direct investment in industrial research in the pharmaceutical and electronics industries--results from a survey of multinational firms," Research Policy, Elsevier, vol. 28(2-3), pages 179-193, March.
- Achilladelis, Basil & Antonakis, Nicholas, 2001. "The dynamics of technological innovation: the case of the pharmaceutical industry," Research Policy, Elsevier, vol. 30(4), pages 535-588, April.
- Bas, Christian Le & Sierra, Christophe, 2002. "'Location versus home country advantages' in R&D activities: some further results on multinationals' locational strategies," Research Policy, Elsevier, vol. 31(4), pages 589-609, May.
- John Cantwell & Elena Kosmopoulou, 2001. "Determinants of Internationalisation of Corporate Technology," DRUID Working Papers 01-08, DRUID, Copenhagen Business School, Department of Industrial Economics and Strategy/Aalborg University, Department of Business Studies.
- Dunning, John H., 1994. "Multinational enterprises and the globalization of innovatory capacity," Research Policy, Elsevier, vol. 23(1), pages 67-88, January.
- Reddy, Prasada, 1997. "New trends in globalization of corporate R&D and implications for innovation capability in host countries: A survey from India," World Development, Elsevier, vol. 25(11), pages 1821-1837, November.
- Schüklenk, Udo, 2000. "Protecting the vulnerable: testing times for clinical research ethics," Social Science & Medicine, Elsevier, vol. 51(6), pages 969-977, September.
- Henry Adobor, 2012. "Ethical Issues in Outsourcing: The Case of Contract Medical Research and the Global Pharmaceutical Industry," Journal of Business Ethics, Springer, vol. 105(2), pages 239-255, January.
- Santiago-Rodriguez, Fernando & Dutrenit, Gabriela, 2010.
"Determinants of PRO-industry interactions in pharmaceutical R&D: the case of Mexico,"
UNU-MERIT Working Paper Series
053, United Nations University, Maastricht Economic and social Research and training centre on Innovation and Technology.
- Santiago-Rodriguez, Fernando & Dutrenit, Gabriela, 2010. "Determinants of PRO-industry interactions in pharmaceutical R&D: the case of Mexico," MERIT Working Papers 053, United Nations University - Maastricht Economic and Social Research Institute on Innovation and Technology (MERIT).
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: (Ad Notten).
If references are entirely missing, you can add them using this form.